Tetradecanoylphorbol Acetate

Subscribe to Selected New Research on Tetradecanoylphorbol Acetate

922 relevant articles (9 outcomes, 57 trials/studies) found for this Bio-Agent

Description: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.

Also Known As:

12-Myristoyl-13-acetylphorbol; 12-O-Tetradecanoyl Phorbol 13-Acetate; Tetradecanoylphorbol Acetate, 4a alpha-Isomer; 12 Myristoyl 13 acetylphorbol; 12 O Tetradecanoyl Phorbol 13 Acetate; 13-Acetate, 12-O-Tetradecanoyl Phorbol; Acetate, Phorbol Myristate; Acetate, Tetradecanoylphorbol; Myristate Acetate, Phorbol; Phorbol 13-Acetate, 12-O-Tetradecanoyl; Tetradecanoylphorbol Acetate, 4a alpha Isomer; Phorbol Myristate Acetate; Tetradecanoic acid, 9a-(acetyloxy)-1a,1b,4,4a,5,7a,7b,8,9,9a-decahydro-4a,7b-dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1H-cyclopropa(3,4)benz(1,2-e)azulen-9-yl ester, (1aR-(1aalpha,1bbeta,4abeta,7aalpha,7balpha,8alpha,9beta,9aalpha))-

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 40

Tetradecanoylphorbol Acetate: 922

12-O-hexadecanoylphorbol-13-acetate: 4

20-oxo-20-deoxy-12-myristate 13-acetate: 3

4-O-methyl-12-O-tetradecanoylphorbol 13-acetate: 3

phorbolol myristate acetate: 2

(5,6)PA: 1

2,3-dihydrophorbol myristate acetate: 1

12-O-(12(N)-dansylaminododecanoyl)phorbol 12,20-diacetate

12-O-(12-N-dansylaminododecanoyl)phorbol

12-O-tetradeca-2,4,6,8-tetranoylphorbol-13-acetate

O-(N-dansylamino-3-tetradecanoyl)-12,O-acetyl-13-phorbol

Experts

1.	Chen, Hsing I: 3 articles (07/2008 - 05/2003)
2.	Huang, Kun-Lun: 2 articles (07/2008 - 04/2008)
3.	Chu, Shi-Jye: 2 articles (04/2008 - 08/2004)
4.	Hsu, Kang: 2 articles (08/2004 - 05/2003)
5.	Wang, David: 2 articles (08/2004 - 05/2003)
6.	Yang, Yi-Ling: 1 article (07/2008)
7.	Liou, Huey-Ling: 1 article (07/2008)
8.	Chen, Chien-Wen: 1 article (04/2008)
9.	Li, Min-Hui: 1 article (04/2008)
10.	Chang, Hung: 1 article (04/2008)

Related Diseases

1.	Neoplasms (Cancer) 06/01/1983 - "Prolonged contact with nanomole to micromole concentrations of the tumor promoter phorbol myristate acetate causes a significant reduction in the lytic activity of cloned cytolytic T cells" 12/01/1992 - "In the present study we investigated the in vitro effects of the tumor promoter phorbol myristate acetate (PMA) on the accessory function of mouse spleen dendritic cells (DC) in mitogenesis" 11/01/1976 - "Fluorescence studies on the interaction of the tumor promoter phorbol myristate acetate and related compounds with rat liver plasma membranes." 09/01/1973 - "Dose-response studies with a pure tumor-promoting agent, phorbol myristate acetate." 05/15/2007 - "Phorbol myristate acetate (PMA, 100 nM) that completely depleted PKC-alpha also enhanced cancer cell proliferation and attenuated VIN-induced cytotoxicity" Order ALL the reference details at left...
2.	Infection 07/01/2001 - "However, the production of O2- by macrophages was undetectable during the first 30 min following infection and no respiratory burst was inducible by phorbol myristate acetate (PMA) 4 h after infection with V. anguillarum" 06/01/2001 - "Ad/t-PA infection of phorbol myristate acetate (PMA)-differentiated MEG-01 cells increased cellular t-PA levels by 120 fold (1580 +/- 130 ng/10(6) cells at 5 MOI) in comparison to non-or Ad/beta-gal-infected cells" 12/01/1998 - "To address this question, we evaluated Leishmania panamensis infection of (1) the human promonocytic/histiocytic cell line U-937 before and after induction of differentiation by phorbol myristate acetate; (2) fresh human peripheral blood monocytes; and (3) macrophages derived from monocytes by differentiation in vitro" 12/12/1997 - "Phorbol myristate acetate (PMA)-induced production of O2-by PMN was decreased for three days after infection in S responders compared to only one day in M responders and was followed by an upregulation" 05/01/1996 - "Untreated THP-1 and phorbol myristate acetate-differentiated THP-1 were permissive for infection and multiplication of intracellular L" Order ALL the reference details at left...
3.	Adult Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 08/01/2000 - "In this study, we tested the effectiveness of early surfactant treatment in a commonly used animal model of acute lung injury, phorbol-myristate acetate (PMA), to see if it would attenuate the progression of lung injury" 04/01/1987 - "In this study, we characterized the procoagulant (PC) and fibrinolytic activities simultaneously present in the alveolar space during the course of acute lung injury induced in rabbits by an intravenous injection of phorbol myristate acetate (PMA)" 07/01/2008 - "Phorbol myristate acetate (PMA) causes acute lung injury (ALI)" 02/01/1999 - "A model of acute lung injury induced by intravenous phorbol myristate acetate (PMA) is described" 01/01/1999 - "Phorbol myristate acetate (PMA) activates neutrophils and causes acute lung injury" Order ALL the reference details at left...
4.	Inflammation 05/01/1994 - "Human peritoneal MO from inflammation-free patients reacted against a human tumour cell line if cultured with LPS and TPA (phorbol-myristate acetate) and were therapeutically effective against the same palpable s.c" 10/01/1995 - "The present study was designed to test the hypothesis that ileal microvascular injury during phorbol myristate acetate (PMA)-induced systemic inflammation is also blocked by MoAB 60.3" 11/04/2008 - "Topical application of phorbol myristate acetate (PMA) elicits intense local inflammation that facilitates outgrowth of premalignant lesions in skin after carcinogen exposure" 11/01/2006 - "Increased levels of macrophage migration inhibitory factor (MIF) in serum, sputum, and bronchioalveolar lavage fluid (BALF) from asthmatic patients and time/dose-dependent expression of MIF in eosinophils in response to phorbol myristate acetate suggest the participation of MIF in airway inflammation" 07/01/2006 - "The treatments were administered as a single dose 30 min after pinna inflammation was induced with tetradecanoylphorbol acetate" Order ALL the reference details at left...
5.	Edema 10/01/1987 - "In a previous study, we demonstrated that a non-toxic concentration of phorbol myristate acetate (PMA) produced edema in isolated rat lungs which were coperfused with neutrophils (PMN)" 08/11/2000 - "Mangicols A and B, however, showed significant antiinflammatory activity in the PMA (phorbol myristate acetate)-induced mouse ear edema model" 06/01/1992 - "Hemodynamic changes, arterial oxygenation, and the development of lung edema were monitored for 4 hrs after phorbol myristate acetate injection to assess the extent of lung damage" 01/01/1995 - "Phorbol-myristate acetate (PMA) is commonly used to produce experimental edema and other tissue injuries in the lung" 06/01/1990 - "Phorbol myristate acetate (PMA), which induces acute pulmonary injury in mammals, induced acute airsacculitis in turkeys after intra-airsac inoculation of 0.1 mg/kg. Grossly, air sacs contained multifocal to diffuse hemorrhage and edema at postinoculation hours (PIH) 3 and 6. Microscopically, there was multifocal congestion and small thrombocyte aggregates within small blood vessels by PIH 0.5, with a few vessels containing small numbers of marginating heterophils" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Zymosan
2.	Tretinoin (Retinoic Acid)
3.	1,3-dimethylthiourea
4.	N-Formylmethionine Leucyl-Phenylalanine
5.	Arachidonic Acid (Vitamin F)
6.	Reactive Oxygen Species (Oxygen Radicals)
7.	Capsaicin (Zostrix)
8.	Gangliosides
9.	Lactic Acid
10.	Sodium Dodecyl Sulfate (Sodium Lauryl Sulfate)

Related Therapies and Procedures

1.	Microspheres (Microsphere)
2.	Aftercare (After-Treatment)
3.	Transplants (Transplant)
4.	Transplantation (Transplant Recipients)
5.	Renal Dialysis (Hemodialysis)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 18530 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>